The recent development of molecular genetics and other stuff regarding targeted therapy continues to demonstrate the potential of fulfilling the promise of precision medicine.we here presented an overview of the management of ROS1-rearranged non–small-cell lung cancer. There can be detailed points over this and in the article you will get study supported by analysis for the same. In one study, 8% (6 of 75 patient samples) of TKI-naive ROS1-rearranged lung cancers had MAPK pathway alterations, many of which were shown to confer resistance. Further it became very important for the Clinical Oncology for using the ROS1.

In one study, 8% (6 of 75 patient samples) of TKI-naive ROS1-rearranged lung cancers had MAPK pathway alterations, many of which were shown to confer resistance.For situations such as this and in the face of multiple, polyclonal resistance mechanisms, standard-of-care options such as a platinum doublet–containing regimen should be considered.All these ROS1 standards are very much clinical and important in proper way to help patients with malignancy.

As a complement to existing guidelines, the roadmap for treating ROS1 fusion–driven NSCLCs provided by Almquist and Ernani provides an approach highlighting the potential utility of molecular profiling at resistance.